The Poche Centre to host 3D total-body imaging system as part of world-first initiative to save lives from melanoma
29 November 2018
Melanoma Institute Australia (MIA) is proud to play a vital role in the Australian Cancer Research Foundation (ACRF) Australian Centre of Excellence in Melanoma Imaging and Diagnosis (ACEMID).
Fifteen 3D total-body imaging systems will be rolled out across Queensland, New South Wales and Victoria with the aim of improving detection of early-stage melanoma and saving lives. MIA’s The Poche Centre will host one of the 3D systems.
It is estimated each 3D imaging machine will be able to provide 3,000 examinations each year, resulting in a total of approximately 100,000 digital ‘avatars’ within three years. This will create a world-wide data set of skin images which will inform clinical studies that will ultimately lead to changes in clinical decision making.
Funded by a highly competitive and prestigious $10 million grant from the ACRF, ACEMID is led by the University of Queensland, along with The University of Sydney and Monash University. It brings together three established NHMRC Centres of Research Excellence (CRE), including the CRE in Melanoma in which MIA leads, to combine cutting-edge imaging technology with a remote medicine network. Melanoma Institute Australia’s team members critical to the initiative include Professor Graham Mann, who is the NSW Chief Investigator (CI), and MIA Co-Medical Director Professor Richard Scolyer and Associate Professor Pascale Guitera who are experts in Diagnostic Intelligence. MIA’s Professor Andrew Spillane and Associate Professor Robyn Saw are Associate Investigators and Associate Professor Anne Cust and Associate Professor Rachael Morton feature in Clinical and Health Service Evaluation roles.
Co-Medical Director of MIA, Professor Richard Scolyer, said the initiative would provide enhanced access to specialist services for patients in rural and remote areas.
‘This infrastructure will provide the foundation for 3D total body imaging to be implemented within a remote medicine network, which is essential in a country as vast as Australia,’ Professor Scolyer said.
‘Three dimensional total body data will be transmitted from 3D imaging systems in geographically diverse locations to centralised image storage repositories, which will enable dermatologists and other skin specialists to review patient images. This will have immense impacts on patients by ensuring they are diagnosed quickly, early and accurately, regardless of where they live.’
The ACRF Australian Centre of Excellence in Melanoma Imaging and Diagnosis is a world first approach to tackling the burden of melanoma, and aims to achieve a “World Without Melanoma”. It will create a multi-disciplinary, multi-site team with the goal of improving the detection and diagnosis of melanoma whilst reducing variability in diagnosis and the incidence of thicker, poorer prognosis melanomas. The initiative also aims to reduce the financial burden of melanoma on the Australian public, decrease consultation times by taking a total-body image in milliseconds, and improve the health equity of rural and remote Australians in regards to melanoma diagnosis.
Olivia is using her Ninja star power to shine a spotlight on melanoma prevention - in memory of her dad.
Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.
New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.
Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate.
A Ninja Warrior legend and Olympic gymnast, Olivia knows first hand the devastating impact of melanoma.
All Australians are urged to join the fight against melanoma this summer.
The ground-breaking work of MIA's Co-Medical Director Prof Richard Scolyer has been recognised with NSW’s highest accolade for cancer research.
A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.
The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.
Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.
Professor Long cites as a highlight of her 2-year Presidency, the phenomenal research output by SMR members who have continued to lead the cancer field despite the impact of COVID-19.
Join in the fun of the virtual event, and together we can run over melanoma!
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.